Literature DB >> 2803327

Activation of the complement system in systemic sclerosis. Relationship to clinical severity.

G Senaldi1, S Lupoli, D Vergani, C M Black.   

Abstract

Using newly developed techniques, we investigated the complement pathways and the extent of their activation in patients with systemic sclerosis (SSc) of both the diffuse cutaneous and limited cutaneous types. Plasma levels of the fragments C3d, C4d, and Ba were measured in patients with SSc and in matched control subjects. All fragments and ratios were higher in SSc patients than in controls (P less than 0.05), demonstrating that complement activation occurs in SSc. Levels of C3d, C3d:C3, Ba, and Ba:factor B were higher in patients with diffuse cutaneous SSc patients than in controls (P less than 0.01). C3d, C3d:C3, C4d, and C4d:C4 levels were also higher in patients with limited cutaneous SSc than in controls (P less than 0.05). These results show that complement activation occurs in SSc patients and that it reflects clinical severity. Complement activation may therefore have a pathogenetic role in SSc, and its measurement may prove useful in monitoring the disease.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2803327     DOI: 10.1002/anr.1780321011

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  19 in total

1.  Serum levels of soluble CD21 in patients with systemic sclerosis.

Authors:  Manabu Tomita; Takafumi Kadono; Norihito Yazawa; Tomohiko Kawashima; Zenshiro Tamaki; Ryuichi Ashida; Hanako Ohmatsu; Yoshihide Asano; Makoto Sugaya; Masahide Kubo; Hironobu Ihn; Kunihiko Tamaki; Shinichi Sato
Journal:  Rheumatol Int       Date:  2010-10-30       Impact factor: 2.631

2.  Fc gamma RII restriction fragment length polymorphism (RFLP): analysis in systemic lupus erythematosus and scleroderma and evidence of an alpha gene duplication.

Authors:  E C Jazwinska; C Olive; P M Hogarth; P A Gatenby; S W Serjeantson
Journal:  Clin Exp Immunol       Date:  1991-01       Impact factor: 4.330

3.  The complement system and systemic sclerosis.

Authors:  C Benbassat; M Schlesinger; C Luderschmidt; G Valentini; G Tirri; Y Shoenfeld
Journal:  Immunol Res       Date:  1993       Impact factor: 2.829

4.  Brief Report: Association of Elevated Adipsin Levels With Pulmonary Arterial Hypertension in Systemic Sclerosis.

Authors:  Benjamin D Korman; Roberta Goncalves Marangoni; Monique Hinchcliff; Sanjiv J Shah; Mary Carns; Aileen Hoffmann; Rosalind Ramsey-Goldman; John Varga
Journal:  Arthritis Rheumatol       Date:  2017-10       Impact factor: 10.995

5.  Sclerotic-type chronic GVHD of the skin: clinical risk factors, laboratory markers, and burden of disease.

Authors:  Kathryn J Martires; Kristin Baird; Seth M Steinberg; Lana Grkovic; Galen O Joe; Kirsten M Williams; Sandra A Mitchell; Manuel Datiles; Fran T Hakim; Steven Z Pavletic; Edward W Cowen
Journal:  Blood       Date:  2011-07-26       Impact factor: 22.113

Review 6.  Innate Immunity in Systemic Sclerosis.

Authors:  Christopher Dowson; Nathan Simpson; Laura Duffy; Steven O'Reilly
Journal:  Curr Rheumatol Rep       Date:  2017-01       Impact factor: 4.592

7.  Influence of C4 null alleles on C4 activation in systemic lupus erythematosus.

Authors:  D C Briggs; G Senaldi; D A Isenberg; K I Welsh; D Vergani
Journal:  Ann Rheum Dis       Date:  1991-04       Impact factor: 19.103

Review 8.  Complement and autoimmunity.

Authors:  Eleonora Ballanti; Carlo Perricone; Elisabetta Greco; Marta Ballanti; Gioia Di Muzio; Maria Sole Chimenti; Roberto Perricone
Journal:  Immunol Res       Date:  2013-07       Impact factor: 2.829

Review 9.  Clinical aspects of systemic sclerosis (scleroderma).

Authors:  R M Silver
Journal:  Ann Rheum Dis       Date:  1991-11       Impact factor: 19.103

10.  Comparative proteomic analysis of serum from patients with systemic sclerosis and sclerodermatous GVHD. Evidence of defective function of factor H.

Authors:  Cinzia Scambi; Valentina La Verde; Lucia De Franceschi; Giovanni Barausse; Fabio Poli; Fabio Benedetti; Marco Sorio; Francesca Deriu; Paola Roncada; Oscar Bortolami; Francesco Turrini; Paola Caramaschi; Chiara Stranieri; Lisa M Bambara; Domenico Biasi
Journal:  PLoS One       Date:  2010-08-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.